Piper Sandler Reiterates Overweight on Sutro Biopharma, Lowers Price Target to $11

Sutro Biopharma -4.83%

Sutro Biopharma

STRO

3.94

-4.83%

Piper Sandler analyst Edward Tenthoff reiterates Sutro Biopharma (NASDAQ: STRO) with a Overweight and lowers the price target from $12 to $11.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via